Provention Bio shares more than triple on diabetes prevention study results
June 10, 2019 at 13:30 PM EDT
Shares of Provention Bio, a New Jersey-based drug company that went public last year, more than tripled Monday after the company's experimental medicine appeared to delay onset of type 1 diabetes in a clinical trial.